Financial Report: Bristol-Myers Squibb 1Q Revenues: $11.6 billion (+5%) 1Q Earnings: $2.0 billion (+4%) Comments: Growth in the quarter was primarily driven by Eliquis and Opdivo, and new product portfolio (primarily cell therapy products and Reblozyl), partially offset by recent loss of exclusivity for Revlimid and Abraxane, and foreign exchange impacts.   Eliquis revenues grew 11% to $3.2 billion. Opdivo revenues increased 12% to $1.9 billion driven by higher demand across multiple indica...